Thursday April 9, 2020

Malin streamlines portfolio to focus on developing four key investments

Brokers react positively to biotech firm’s new strategy

Ian Guider

Markets Editor

@ianguider
11th November, 2018
Malin’s chief financial officer Darragh Lyon

Malin, the drug and biotech company, has said it will have sufficient cash to follow its money on key investments.

The company is slimming down its portfolio of 18 investments to focus on four potentially valuable companies.

Malin’s chief financial officer Darragh Lyons told The Sunday Business Post that while there might be requirements for these companies to raise more money, Malin would be able to meet its commitments through its existing cash, an undrawn European...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

What’s coming up today and what you might have missed

Hannah O’Brien | 3 months ago

What’s coming up today and what you might have missed.

Hannah O’Brien | 3 months ago